Investor presentation, 2 June 2017

Investor Presentation‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌

2 June 2017

1

Forward looking statements

This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.

2

Neuren snapshot

• Stock code ASX: NEU, market cap approximately A$120 million (US$90 million)

• Developing new treatments for neurological conditions

  • Significant unmet needs and commercial opportunities with no approved drugs

  • Regulatory advantages - candidates for Fast Track, Orphan Drug, Breakthrough Therapy

  • Strong support from advocacy groups and leading physicians

• Lead drug candidate trofinetide

  • Clinical improvement in Rett syndrome and Fragile X syndrome Phase 2 trials

  • Broad range of effects consistent with known normalising actions on brain function

  • Excellent safety and tolerability profile

• Lead Orphan Drug program - Rett syndrome

  • Seriously debilitating and life-threatening disorder, with no approved medicines

  • Statistically significant and clinically meaningful improvement in Phase 2 trial

  • Active collaboration and strong support from leading physicians and largest advocacy group (rettsyndrome.org)

  • Anticipating Phase 3 discussions with FDA Division of Neurology in Q3 2017

3

Issued shares: 1.84 billion 1 month VWAP : 6.4 cents Closing price 31 May 2017: 6.5 cents 52 week range: 4.1 - 9.4 cents

Langley

Walker, 19% Management,

11%

Retail, 63%

4